HSC Exam Practice

Sample response. An environmental disease is a non-infectious disease caused or triggered by exposure to external agents — physical, chemical or biological — rather than being primarily determined by inherited genetic variants alone. A genetic disease is present due to mutations or variants in an individual’s inherited DNA that are present from conception, regardless of environmental exposure.

Marking notes. 1 mark for defining environmental disease as caused by external agents / exposures (not inherited genes); 1 mark for distinguishing from genetic disease (present due to inherited DNA variants, not requiring external exposure).

Sample response. The dose-response relationship describes the pattern in which increasing cumulative exposure to an environmental agent produces increasing levels of disease risk. For tobacco smoking, each cigarette delivers carcinogens (e.g. benzopyrene) that form DNA adducts in bronchial epithelial cells. A single adduct rarely causes cancer — most are repaired or cause non-consequential changes. Cancer requires multiple mutations in key genes (TP53, KRAS) in the same cell line. More smoking (higher dose) → more adducts per cell per year → higher probability that sufficient mutations accumulate → higher lung cancer risk. This is quantified by pack-years: a 40-pack-year smoker has substantially greater risk than a 5-pack-year smoker.

Marking notes. 1 mark for correctly defining dose-response (more exposure = more risk, proportional / probabilistic); 1 mark for applying it to tobacco (more carcinogens → more DNA adducts → higher mutation probability); 1 mark for explaining why a single exposure is insufficient (multiple mutations required; cancer is a multi-step process) OR for naming pack-years as the dose measure.

Sample response. UV-B radiation causes the formation of thymine dimers (cyclobutane pyrimidine dimers, CPDs) in skin cell DNA. The mechanism: UV-B photons are absorbed by adjacent thymine bases on the same DNA strand. The absorbed energy drives a photochemical reaction in which a covalent cyclobutane ring forms between the C4 and C5 carbons of the two adjacent thymines, linking them together. This distorts the DNA double helix at that site, preventing normal Watson-Crick base pairing and blocking DNA polymerase progression during replication.

Marking notes. 1 mark for correctly naming thymine dimer (accept CPD or cyclobutane pyrimidine dimer); 1 mark for explaining mechanism (UV-B photon absorbed by adjacent thymines → photochemical reaction forms covalent cyclobutane ring); 1 mark for consequence (distorts helix, blocks replication / prevents base pairing).

Sample response. A genetic mutation in CDKN2A involves an actual change in the DNA nucleotide sequence — for example, a point mutation creating a premature stop codon that produces a non-functional p16 protein or no p16 at all. The nucleotide sequence is permanently altered. DNA methylation of the CDKN2A promoter is an epigenetic change: methyl groups (–CH3) are added to cytosine bases at CpG sites in the promoter region. The nucleotide sequence of CDKN2A remains intact, but methyl-binding proteins compact the chromatin and prevent transcription factors from binding, silencing the gene. Both achieve the same functional outcome (p16 protein absent → CDK4/6 uninhibited → cell cycle checkpoint lost), but methylation does not permanently alter the DNA sequence and may be partially reversed by demethylating agents.

Marking notes. 1 mark for correctly describing genetic mutation (sequence change, e.g. point mutation → non-functional p16); 1 mark for correctly describing DNA methylation (methyl groups on cytosine at CpG sites → transcription factor blocked → gene silenced without sequence change); 1 mark for identifying the key distinction (mutation = sequence altered; methylation = sequence intact, expression changed; OR noting reversibility difference).

Sample response. When asbestos fibres are inhaled, long fibres (>5 μm) lodge in the pleural lining and cannot be fully engulfed by alveolar macrophages — a process called frustrated phagocytosis. The macrophages attempt repeatedly to phagocytose the fibres but fail to degrade them, releasing reactive oxygen species (ROS) and inflammatory cytokines chronically into the surrounding tissue. These ROS directly oxidise DNA bases in neighbouring mesothelial cells, causing strand breaks and base modifications. Over 20–50 years, cumulative ROS-mediated DNA damage in mesothelial cells produces mutations in tumour suppressor genes (BAP1, NF2, CDKN2A). This mechanism is physical because asbestos itself is chemically inert: it does not react chemically with DNA. The damage arises from the physical inability of macrophages to digest the durable fibres, not from any chemical reactivity of the asbestos.

Marking notes. 1 mark for correctly naming frustrated phagocytosis and explaining the macrophage failure; 1 mark for the ROS mechanism (frustrated macrophages release ROS → oxidative DNA damage in mesothelial cells); 1 mark for explaining why “physical” is correct (asbestos is chemically inert; damage is caused by the physical inability to degrade the fibre, not by chemical bonding to DNA).

Sample response. Lung cancer pathway: tobacco carcinogens (e.g. benzopyrene) are metabolically activated in bronchial epithelial cells to reactive electrophiles that covalently bond to DNA bases, forming DNA adducts. These adducts cause errors during replication → mutations in TP53 (tumour suppressor — disabling apoptosis and cell cycle arrest) and KRAS (proto-oncogene — activating growth signals). Accumulated mutations over 20–30 years → uncontrolled cell division → lung cancer. This mechanism involves direct DNA mutation leading to cell cycle dysregulation [2 marks]. COPD (emphysema) pathway: tobacco smoke irritants (not primarily the carcinogens) trigger chronic inflammation in the airways. Recruited macrophages and neutrophils release elastase, a protease that degrades elastin in alveolar walls. Progressive elastin destruction reduces alveolar gas exchange surface area and eliminates elastic recoil → emphysema. Simultaneously, goblet cell hyperplasia → mucus hypersecretion → airway obstruction (chronic bronchitis). This mechanism involves tissue destruction through chronic inflammation, not DNA mutation [2 marks]. Key difference: lung cancer involves mutagenic DNA damage causing uncontrolled cell division; COPD involves inflammatory tissue destruction without (primarily) oncogenic mutation.

Marking notes. Lung cancer: 1 mark for DNA adducts → mutations in TP53/KRAS mechanism; 1 mark for linking to cell cycle dysregulation / uncontrolled division. COPD: 1 mark for inflammation → elastase → elastin destruction / alveolar wall loss mechanism; 1 mark for identifying the key difference (mutation vs tissue destruction).

Sample response (a). The apparent contradiction is explained by the 20–30 year latency period between first tobacco exposure and the development of clinical lung cancer. Smoking prevalence peaked at approximately 72% around 1945 — this represents the period when the largest cohort of Australian men began accumulating high-dose tobacco carcinogen exposure. Lung cancer develops only after sufficient mutations accumulate in bronchial cells over decades. The cohort of men who smoked heavily in the 1940s–1960s began to manifest lung cancer in the 1960s–1980s, producing the mortality peak in 1985. The decline in smoking rates from 1945 reduced future exposures, but the large “already-exposed” cohort continued to develop cancer across subsequent decades, sustaining high mortality well after smoking rates had fallen.

Marking notes (a). 1 mark for identifying and defining the latency period (20–30 years between exposure and disease); 1 mark for applying this to the data (peak smoking 1945 → peak mortality ~40 years later, 1985); 1 mark for explaining the mechanism behind the lag (multiple mutations must accumulate over decades in the same cell line before cancer manifests).

Sample response (b). Male lung cancer mortality is predicted to continue declining from 2020 to 2045. The dose-response relationship predicts that lower cumulative tobacco exposure (the 2020 cohort has ~11% smoking prevalence vs ~35% in 1985) will produce fewer DNA adducts per population per year, reducing the rate of new cancer initiations. Due to the 20–30 year latency, the cohort exposed at the current (low) smoking prevalence will begin to show lower cancer rates from approximately 2030–2035 onwards. The declining mortality trend visible from 1985 to 2020 (78 → 42 per 100,000) is expected to continue as progressively less-exposed cohorts age into the at-risk period. Improvements in early detection (LDCT screening) and targeted therapies (EGFR/ALK inhibitors) may further accelerate the decline in mortality independently of incidence.

Marking notes (b). 1 mark for predicting continued decline; 1 mark for applying dose-response reasoning (lower smoking prevalence → fewer mutations per cohort → lower future cancer rate); 1 mark for applying latency (current low-exposure cohort will not show benefits in mortality for 20–30 years, but trend is already visible from historical decline).

Sample response. Epigenetic changes are heritable alterations in gene expression that do not involve changes to the DNA nucleotide sequence. The primary mechanism in cancer biology is DNA methylation: the addition of methyl groups (–CH3) to cytosine bases at CpG dinucleotide sites in gene promoters, catalysed by DNA methyltransferase enzymes. Methylated promoters attract methyl-binding proteins that compact chromatin and block transcription factor access, silencing the gene without altering its sequence. Tobacco smoke causes hypermethylation of the CDKN2A promoter in bronchial epithelial cells. The CDKN2A gene encodes p16, a tumour suppressor protein that inhibits cyclin-dependent kinases CDK4 and CDK6. When p16 is absent (whether by sequence mutation or epigenetic silencing), CDK4/6 remain active → the retinoblastoma protein (Rb) is hyperphosphorylated → E2F transcription factors are released → the cell proceeds through the G1/S checkpoint without normal arrest for DNA repair. The result is functionally identical to a loss-of-function mutation in CDKN2A: unregulated cell cycle progression that contributes to cancer initiation. This reveals the first major insight: epigenetic changes and genetic mutations can produce the same oncogenic functional outcome through different molecular mechanisms. The significance for environmental disease is profound. DNA mutations were long considered the exclusive mechanism by which carcinogens cause cancer. The discovery that environmental exposures also reprogram the epigenome shows that mutagenesis is only one arm of environmental carcinogenesis. Tobacco smoke, air pollution, UV radiation, and diet can all alter methylation patterns and histone modifications across multiple genes simultaneously, affecting cell cycle regulators, apoptosis pathways, and DNA repair enzymes. Epigenetic changes also provide a mechanism for gene-environment interaction at the population level that genetic mutation alone cannot explain. Individuals carry different baseline DNA methylation patterns and different epigenetic regulatory variants. A person with reduced expression of DNA methyltransferase inhibitors may be more susceptible to tobacco-induced hypermethylation of CDKN2A for the same cigarette dose. This produces differential disease risk from identical environmental exposures based on inherited genetic variation in epigenetic regulation — a form of multifactorial disease that combines genetic predisposition with environmental epigenetic reprogramming. Furthermore, unlike most genetic mutations (which are permanent), some epigenetic changes are reversible. Smoking cessation is associated with partial reduction in tobacco-induced methylation patterns over time. Demethylating drugs (5-azacytidine) can reactivate silenced tumour suppressors clinically in some haematological cancers. This reversibility means that environmental epigenetic changes create a window for intervention that genetic mutations do not. Evaluating significance: DNA adduct-driven mutation (the classical tobacco carcinogenesis pathway via TP53 and KRAS) and epigenetic silencing (CDKN2A methylation) are not competing explanations but complementary mechanisms that converge on the same oncogenic outcome. Both are required for a complete understanding of how environmental exposures cause cancer. The epigenetic mechanism extends the multifactorial disease model: cancer risk is not only a function of cumulative mutagenic dose (dose-response) and genetic predisposition (DNA repair efficiency), but also of environmentally induced epigenetic reprogramming that is itself modifiable by both environment and genes. This integration is the current understanding of gene-environment interaction in environmental cancer biology.

Marking criteria.

1 mark — Defines epigenetics correctly: heritable change in gene expression without change to DNA nucleotide sequence.

1 mark — Describes DNA methylation mechanism correctly: methyl groups on cytosine at CpG sites in promoter → transcription factor blocked → gene silenced.

1 mark — Applies mechanism specifically to CDKN2A: tobacco smoke → CDKN2A hypermethylation → p16 absent → CDK4/6 active → Rb phosphorylated → G1 checkpoint lost → uncontrolled division.

1 mark — States and explains that epigenetic silencing produces the same functional outcome as loss-of-function mutation (both remove p16 checkpoint) through a different mechanism that does not alter the DNA sequence.

1 mark — Evaluates significance vs direct DNA mutation: epigenetics is an additional, not alternative, pathway; both converge on the same oncogenic consequence; environmental carcinogenesis requires both models.

1 mark — Explains gene-environment interaction: differential epigenetic susceptibility based on inherited genetic variation in epigenetic regulators modifies individual cancer risk from the same environmental exposure.

1 mark — Discusses reversibility as a key distinction: epigenetic changes may be partially reversed (cessation, demethylating drugs); most DNA sequence mutations are not — this creates an intervention window unique to epigenetic mechanisms.

2 marks — Integrated synthesis: explicitly connects epigenetic changes, direct mutation, dose-response, genetic predisposition, and multifactorial disease into a coherent evaluative framework using precise terminology throughout. Must demonstrate Band 5–6 evaluative structure (claim → evidence → significance → qualified conclusion), not merely list facts.